Product Description
Basimglurant is a highly promising antidepressant drug now in clinical development for depression. a novel negative allosteric modulator of metabotropic glutamate receptor 5 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26219727/)
Mechanisms of Action: MGLUR5 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Neuralgia|Trigeminal Neuralgia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, Germany, India, Israel, Italy, Poland, Spain, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Trigeminal Neuralgia
Phase 2: Tuberous Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05059327 |
NOE-TSC-201 | P2 |
Completed |
Tuberous Sclerosis |
2025-02-06 |
12% |
2025-06-05 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2024-514497-41-00 |
NOE-TGN-201 | P3 |
Recruiting |
Trigeminal Neuralgia |
2026-05-01 |
2025-05-02 |
Treatments |
|
2024-512611-53-00 |
NOE-TSC-201 | P2 |
Completed |
Tuberous Sclerosis |
2025-03-17 |
2025-05-02 |
Treatments |
|
NCT05217628 |
NOE-TGN-201 | P3 |
Active, not recruiting |
Trigeminal Neuralgia |
2027-02-02 |
13% |
2026-01-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2021-001866-39 |
A Phase II/III efficacy and safety study of basimglurant in patients with trigeminal neuralgia | P3 |
Active, not recruiting |
Trigeminal Neuralgia |
2025-05-05 |
2025-05-06 |
Treatments |